project id: TCGA-PRAD; case submitter id: TCGA-ZG-A8QY; source center: 23; state: released; a260 a280 ratio: 1.84; normal tumor genotype snp match: Yes; ribosomal rna 28s 16s ratio: 1.31; rna integrity number: 7.8; age at index: 67; days to birth: -24731; ethnicity: not hispanic or latino; gender: male; race: white; vital status: Alive; year of birth: 1946; age at diagnosis: 24731; ajcc clinical m: M0; ajcc clinical t: T2c; ajcc pathologic n: N1; ajcc pathologic t: T3b; classification of tumor: not reported; days to diagnosis: 0; days to last follow up: 404.0; icd 10 code: C61; last known disease status: not reported; morphology: 8140/3; primary diagnosis: Adenocarcinoma, NOS; primary gleason grade: Pattern 5; prior malignancy: no; prior treatment: No; progression or recurrence: not reported; secondary gleason grade: Pattern 4; site of resection or biopsy: Prostate gland; synchronous malignancy: No; tissue or organ of origin: Prostate gland; tumor grade: Not Reported; year of diagnosis: 2013; treatment or therapy: no; alcohol history: Not Reported; is ffpe: false; composition: Not Reported; days to collection: 250; initial weight: 160.0; sample id: 432df7ed-ade9-4643-b4e2-79bed9485eb9; sample submitter id: TCGA-ZG-A8QY-01A; portion id: 73989a2f-de8c-451e-88b0-ea39af6cf805; portion submitter id: TCGA-ZG-A8QY-01A-11; slide id: bfe95b53-91f9-4359-ba28-e78e29018ce0; slide submitter id: TCGA-ZG-A8QY-01A-01-TSA; percent lymphocyte infiltration: 0.0; percent monocyte infiltration: 0.0; percent necrosis: 0.0; percent neutrophil infiltration: 0.0; percent normal cells: 10.0; percent stromal cells: 30.0; percent tumor cells: 60.0; percent tumor nuclei: 80.0; section location: TOP;